NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $0.37 -0.01 (-2.66%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Biodexa Pharmaceuticals alerts: Email Address About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BDRX alerts:Sign Up Key Stats Today's Range$0.36▼$0.3850-Day Range$0.37▼$1.0852-Week Range$0.35▼$8.81Volume120,755 shsAverage Volume2.49 million shsMarket Capitalization$471,042.00P/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More… Who are Nvidia’s New Silent Partners? (Ad)Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 59th PercentileBiodexa Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodexa Pharmaceuticals has received no research coverage in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biodexa Pharmaceuticals are expected to grow in the coming year, from ($0.12) to ($0.08) per share.Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.67% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 17.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.67% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 17.72%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.33 News SentimentBiodexa Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biodexa Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BDRX Stock News HeadlinesADR Ratio ChangeSeptember 19 at 4:30 PM | globenewswire.comAnnounces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantSeptember 16, 2024 | finance.yahoo.comTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 20, 2024 | Porter & Company (Ad)Receipt of Nasdaq Delisting Determination - Plans to AppealAugust 30, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Flat in Monday TradingAugust 12, 2024 | msn.comAnnounces Closing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 23, 2024 | globenewswire.comAnnounces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 19, 2024 | globenewswire.comPositive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024July 2, 2024 | globenewswire.comSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $2.68 at the beginning of 2024. Since then, BDRX shares have decreased by 86.3% and is now trading at $0.3660. View the best growth stocks for 2024 here. When did Biodexa Pharmaceuticals' stock split? Biodexa Pharmaceuticals shares reverse split on Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDRX CUSIPN/A CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+2,085.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$381,000.00 Price / Sales1.24 Cash FlowN/A Price / Cash FlowN/A Book Value$3.93 per share Price / Book0.09Miscellaneous Outstanding Shares1,287,000Free Float1,283,000Market Cap$471,042.00 OptionableNot Optionable Beta1.45 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BDRX) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.